MICHAEL LUTTEROPP

City:

BERGISCH GLADBACH

Country:

Germany

Published Applications:

Last publication date:

2024-09-26

Top Assignees for applications by MICHAEL LUTTEROPP

The entities that hold a legal rights for patent applications filed by inventor LUTTEROPP MICHAEL:

MILTENYI BIOTEC B.V. & CO. KG 5 Bergisch Gladbach, Germany
Miltenyi Biotec GmbH 2 Bergisch-Gladbach, Germany
Miltenyi Biotec B.V. & Co. KG 1 Bergisch Gladbach, Germany
MILTENYI BIOTEC B.V. & CO. KG 1 Cupertino, CA United States
Mitenyi Biotec B.V. & Co. Kg 1 Bergisch Gladbach, Germany
MILTENYI BIOTEC B.V. & CO. KG 1 Gladbach, Germany

Recent patent applications by LUTTEROPP MICHAEL

MICHAEL LUTTEROPP from BERGISCH GLADBACH, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-09-26

US20240316192A1

Human necessities

Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens

#2 | 2024-09-19

US20240307533A1

Human necessities

Reducing side effects of immunotherapy using genetically modified hematopoietic cells

#3 | 2024-08-15

US20240269275A1

Human necessities

Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen

#4 | 2023-08-10

US20230248823A1

Human necessities

Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form

#5 | 2021-12-30

US20210401980A1

Human necessities

Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells

#6 | 2021-11-04

US20210338814A1

Human necessities

COMBINATION OF IMMUNE EFFECTOR CELLS SPECIFIC FOR A TARGET ANTIGEN AND HEMATOPOIETIC CELLS THAT EXPRESS THE TARGET ANTIGEN IN AN ALTERED FORM

#7 | 2018-10-04

US20180280502A1

Human necessities

Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form

#8 | 2016-05-26

US20160144026A1

Human necessities

Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases

InventorID:

1538595 ⎘